Table 5 Incremental Cost-Effectiveness Ratios Comparing Three Strategies in China and the USA
| Â | China | USA | ||
|---|---|---|---|---|
Full-dose sorafenib vs TACE | Dose-adjusted sorafenib vs full-dose sorafenib | Full-dose sorafenib vs TACE | Dose-adjusted sorafenib vs full-dose sorafenib | |
Incremental cost per person ($) | 6061.73 | -6215.23 | −60,870.43 | −10,812.73 |
Incremental QALYs per person (years) | 0.060 | 0.047 | 0.060 | 0.047 |
Incremental cost per QALY (ICER, $) | 101,028.83 | −132,238.94 | −1,014,507.20 | −230,058.09 |